Pfizer Inc. $PFE Shares Sold by KBC Group NV

KBC Group NV trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 7.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,471,914 shares of the biopharmaceutical company’s stock after selling 721,799 shares during the quarter. Pfizer accounts for approximately 0.6% of KBC Group NV’s portfolio, making the stock its 22nd largest holding. KBC Group NV’s holdings in Pfizer were worth $237,892,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. SEB Asset Management AB acquired a new stake in shares of Pfizer in the 1st quarter valued at approximately $37,407,000. Swiss National Bank grew its holdings in Pfizer by 7.1% during the first quarter. Swiss National Bank now owns 16,686,212 shares of the biopharmaceutical company’s stock worth $468,549,000 after acquiring an additional 1,106,200 shares during the period. Valley Wealth Managers Inc. raised its position in Pfizer by 28.0% in the first quarter. Valley Wealth Managers Inc. now owns 948,832 shares of the biopharmaceutical company’s stock worth $26,643,000 after acquiring an additional 207,642 shares in the last quarter. AIA Group Ltd lifted its holdings in Pfizer by 14.7% in the first quarter. AIA Group Ltd now owns 833,363 shares of the biopharmaceutical company’s stock valued at $23,401,000 after acquiring an additional 106,683 shares during the period. Finally, Mediolanum International Funds Ltd lifted its holdings in Pfizer by 799.8% in the first quarter. Mediolanum International Funds Ltd now owns 1,373,098 shares of the biopharmaceutical company’s stock valued at $38,131,000 after acquiring an additional 1,220,491 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Recent commentary continues to focus on Pfizer’s pipeline potential, with articles asking whether the company can strengthen its growth story through new drug development and recent approvals, which could support a longer-term rebound. Can Pfizer (NYSE:PFE) Strengthen Its Pipeline Story?
• Positive Sentiment: Pfizer remains attractive to income-focused investors, with coverage highlighting it as a high-yield dividend stock and a potential “buy on the dip” name, which may help limit downside. 3 High-Yield Dividend Stocks to Buy and Hold
• Neutral Sentiment: Analysts are still modeling solid full-year earnings, but Erste Group slightly trimmed its FY2026 EPS estimate for Pfizer to $2.92 from $2.95, signaling only a small downward revision versus the consensus of $2.96.
• Neutral Sentiment: Another valuation-focused note said Pfizer looks “fairly priced” given mixed pipeline risks, suggesting the stock may not be obviously cheap despite its lower valuation and high dividend.
• Negative Sentiment: Pfizer suspended sales of Premarin vaginal cream in India because of supply challenges, adding another operational headwind for the company. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
• Negative Sentiment: Arbutus Biopharma filed international patent lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in mRNA vaccines, keeping legal risk and potential costs in focus for PFE. Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech…

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PFE. BMO Capital Markets lowered their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a report on Tuesday, June 9th. Bank of America lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Finally, Morgan Stanley increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.50.

Pfizer Stock Up 0.1%

Pfizer stock opened at $25.08 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm has a market capitalization of $142.94 billion, a price-to-earnings ratio of 19.15 and a beta of 0.35. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The stock’s fifty day moving average is $25.21 and its two-hundred day moving average is $26.18.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.